Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3351533 | 0.74 | ACACB (0.47) | ACACBALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL3351541 | 0.74 | ACACB (0.47) | ACACBALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL4497893 | 0.73 | SYK (0.35) | ALDH1A1HPGDKDM4E | |
| SCHEMBL16435008 | 0.71 | ACACB (0.43) | ACACBALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL2163983 | 0.69 | HTR2B (0.39) | ALDH1A1KDM4E | |
| SCHEMBL2165249 | 0.69 | KDM4E (0.39) | ALDH1A1MEN1KMT2AKDM4EHSD17B10 | |
| SCHEMBL3352484 | 0.68 | ACACB (0.43) | ACACBALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL10187968 | 0.67 | ACACB (0.39) | ACACBALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL1285654 | 0.67 | ACACB (0.39) | ACACBALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL1285780 | 0.67 | ALDH1A1 (0.41) | ACACBALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528129-B2 | CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-05 | — | — | US | disclosed |
| US-20060252931-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252931-A1 | New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | ACACB 4862/4885ALDH1A1 1872/4885HPGD 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.